Outcomes following a diagnosis of colorectal cancer

Structure of talk

Present and critically review studies available in the literature

- Incidence by ethnic group
- Stage at presentation
- Survival
- •Outcomes in the context of inflammatory bowel disease

Current SEER data for CRC (Archie Bleyer)

138 CRC patients <40 years compared to 339 patients >60 years (Taiwan)

- •14.5% mucin producing (cf 4.7%)
- •7.2% poorly differentiated (cf 3.3%)
- More advanced stage
- •Operative mortality lower (0.7% vs 5%)
- •Cancer specific survival reported to be similar in Stages I-III, better in stage IV

110 Singaporean patients <40 years (5.1%) compared to 2064 >40 years

- Predisposing conditions and genetic factors in 21% vs 2%
- No difference in stage or site at presentation
- No difference in characteristics (mucinous &c)
- Mean follow up of 32 months
- •5YOS 55% vs 54%

Norwegian Rectal Cancer Project

- 1,354 patients younger than aged 70 years treated for cure
 - •45 patients younger than aged 40 years (3%)
 - •significantly higher frequencies of poorly differentiated tumors (27 vs. 12-16 percent; P = 0.014)
 - •N2-stage (37 vs. 13-18 percent; P = 0.001)

	Metastasis	5YOS
Under 40 years	38%	54%
Over 40 years	20-26%	71-88%

Turkey

136 patients under 45 years (20%) among 680 total

- 10 patients with family history
- •Of patients considered resectable (118), 61 (45%) were found to be metastatic at operation

Egypt

1608 CRC in 4 hospitals (85% of national burden)

- •35.6% under 40 years, constant over time and site
- •>50% rectal cancers
- •30.6% mucin producing (cf 14% over 40 years)

Retrospective review of 186 patients younger than 40 years at MDACC

- •median age 34.3 years, median follow-up 9.4 years
- •Stage III-IV 66%
- •Histopathologic indicators of more aggressive tumor biology were present at a significantly higher frequency in young patients compared with patients older than 40 years (p < 0.001).
 - Poorly differentiated tumor grade 41%
 - •signet-ring cell tumors 11%
 - •infiltrating tumor leading edges 69%

Retrospective review of 62 patients OHSU

- •3.1% of total CRC population
- •48% metastatic at diagnosis
- Stage for stage, similar survival

50 patients Harbor-UCLA medical centre 1956-85

- •7-39 years of age
- •2 inflammatory bowel disease, 3 FAP
- •45% Dukes C, 23% Dukes D
- •5YOS 28%

French retrospective survey

- •4643 cases of CRC 1976-96
- •146 under 45 years (3%)
- •Stage III patients more frequent in younger patients
- Post-operative mortality lower under 45 years (2.1% vs 8.4%)
- •Stage for stage, survival better for under 45 years compared to over 45 years
- Gender prognostic in multivariate analyses

NCI in Milan

- •27 patients <30 years, 7 patients <18 years
- Under 18 years
 - •5/7 unfavourable histology
 - •6/7 advanced disease at diagnosis
 - 6/7 relapsed/progressed
 - •5 died
 - •23% 5YOS
- •19-29 years
 - •72% 5YOS

39 patients under 30 years of age

- •6 had Family history, 4 index cases of FAP
- •Rectal cancers in 43%
- •70% at advanced stage
- •11 deaths, 3 alive with disease, 14 no evidence of disease (of 29 curative resections attempted)

Pediatr Blood Cancer. 2008;50(3):588-93. Colorectal carcinoma in children and adolescents: the experience of the Istituto Nazionale Tumori of Milan, Italy.

Colorectal Dis. 2004 May;6(3):191-4. Colorectal cancer in the young: a 12-year review of patients 30 years or less.

South Korean

28 CRC patients under 20 years

- Location evenly distributed
- Mucinous cancers more common
- •22/28 stage III or IV
- •5YOS 21%

Malaysia

21 patients under 30 years

- •Ethnic Chinese>Malay>Indian
- •25% caecal, mucinous and advanced stage dominated
- •5YOS 25%

Surgical outcomes

53 patients with FAP treated with ileal pouch-anal anastamosis (IPAA)

- •31 under 40 years, 22 over 40 years
- No difference in functional outcomes and QoL
- Less nocturnal bowel movements in younger patients at 1 and 3 years
- •Fewer bowel movements/day than older patients at all stages of follow up

Inflammatory bowel disease and cancer

290 patients with IBD-associated CRC (241 with chronic ulcerative colitis and 49 with Crohn's disease) compared to sporadic CRC patients at the Mayo Clinic

- •The median age at diagnosis of IBD-related CRC was 48 years
- •55% of IBD-related tumors were distal to the splenic flexure compared with 78% of sporadic tumors
- •5YS
 - •163 IBD-associated CRC patients=54%,
 - •164 sporadic CRC patients=53%

Inflammatory bowel disease and cancer

Danish population-based registry

- •279 patients with UC-associated CRC
 - Younger (median age of onset 63 vs 71 years)
 - Stage similar to overall CRC
 - Mortality rate ratios higher
 - •1.24 (95% CI 1.02-1.51)
- •100 patients with CD-associated CRC
 - Younger age of onset
 - Stage similar
 - Hazard ratio higher
 - •1.82 (95% CI 1.36-2.43)

COMPLIANCE WITH SCREENING PROGRAMMES NOT REPORTED

Am J Gastroenterol. 2007 102(1):163-7. Survival after colorectal cancer in patients with Crohn's disease: A nationwide population-based Danish follow-up study.

Am J Gastroenterol. 2006 101(6):1283-7. Survival after colorectal cancer in patients with ulcerative colitis: a nationwide population-based Danish study.

Age	Number	Stage	Survival (5YS)
<40	186	More advanced	NA
<45	146	More advanced	No effect (corr. for stage)
<45	136	45% Advanced	NA
<40	110	No age effect	55%
<40	62	58% Advanced	NA
<40	138	No age effect	No effect (corr. for stage)
<40	45	38%	54% (cf 71-88%)
<40	50	28%	28%
<30	21	NA	25%
<30	39	70% Advanced	NA
<20	28	NA	21%
<20	7	84%	23%

Data is

- Heterogeneous
- •Retrospective, historical
- Often uncontrolled

Data is

- Heterogeneous
- •Retrospective, historical
- Often uncontrolled

Age and stage

•Consistently more advanced disease in younger populations

Data is

- Heterogeneous
- Retrospective, historical
- Often uncontrolled

Age and stage

Consistently more advanced disease in younger populations

Age and survival

- •Under 45 years, little consistent effect independent of stage
- •Under 30 years of age, ? survival may be worse allowing for stage

Data is

- Heterogeneous
- Retrospective, historical
- Often uncontrolled

Age and stage

•Consistently more advanced disease in younger populations

Age and survival

- •Under 45 years, little consistent effect independent of stage
- •Under 30 years of age, ? survival may be worse allowing for stage

Age and surgical outcomes

•The young do better

Data is

- Heterogeneous
- Retrospective, historical
- Often uncontrolled

Age and stage

•Consistently more advanced disease in younger populations

Age and survival

- •Under 45 years, little consistent effect independent of stage
- •Under 30 years of age, ? survival may be worse allowing for stage

Age and surgical outcomes

•The young do better

Inflammatory bowel disease and outcomes

- Suggestion that hazard ratio for death from CRC is increased
- •No data on psychosocial factors and adherence to surveillance

NCI AYA Cancer Biology Workshop, June 9-10, 2009

The ABCs of
Acute Lymphoblastic Leukema,
Breast Cancer and
Colon Cancer
in Adolescent and Young Adult (AYA)
Americans

Archie Bleyer, MD

in recognition of the 10th anniversary of the 1st NCI AYAO Workshop (June 1999)




NCI AYA Cancer Biology Workshop, June 9-10, 2009

Incidence since 2000


Colon Cancer

Incidence, 2000-2006, SEER17*

ALL, Colon Cancer, Breast Cancer




Relative Incidence of Top 12 Most Frequent Types of Cancer Age 15-39, 2000-2004, SEER17




Relative Incidence of Top 10 Most Frequent Types of Cancer in Males <40 Years of Age, by 5 Year Intervals

ICD, 2000-2004 SEER17



Relative Incidence of Top 10 Most Frequent Types of Cancer in Females 15-39 Years of Age by 5-Year Intervals

ICD, 2000-2004 SEER17




NCI AYA Cancer Biology Workshop, June 9-10, 2009


Survival 2000-2006

Colon Cancer


5-Year Relative Survival, 2000-2006, SEER 17




5-Year Relative Survival, Colon Cancer, 2000-2006, SEER17 with 2º polynomial regressions




5-Year Relative Survival, Colon Cancer, 2000-2006, SEER17 with 2º polynomial regressions




5-Year Relative Survival, Colon Cancer, 2000-2006, SEER17 with 2º polynomial regressions




5-Year Relative Survival, Colon Cancer, 2000-2006, SEER17 with 2º polynomial regressions



5-Year Relative Survival, 1975-1997 by Calendar Year, SEER9 Colon Cancer





Average Annual % Change (AAPC) 5-Year Relative Survival Colon Cancer

1975 to 1997, SEER9

